146 related articles for article (PubMed ID: 8324868)
1. Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis.
Grunberg SM; Lane M; Lester EP; Sridhar KS; Mortimer J; Murphy W; Sanderson PE
Cancer Chemother Pharmacol; 1993; 32(4):268-72. PubMed ID: 8324868
[TBL] [Abstract][Full Text] [Related]
2. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.
Beck TM; Hesketh PJ; Madajewicz S; Navari RM; Pendergrass K; Lester EP; Kish JA; Murphy WK; Hainsworth JD; Gandara DR
J Clin Oncol; 1992 Dec; 10(12):1969-75. PubMed ID: 1453211
[TBL] [Abstract][Full Text] [Related]
3. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis.
Hesketh PJ; Harvey WH; Harker WG; Beck TM; Ryan T; Bricker LJ; Kish JA; Murphy WK; Hainsworth JD; Haley B
J Clin Oncol; 1994 Mar; 12(3):596-600. PubMed ID: 8120559
[TBL] [Abstract][Full Text] [Related]
5. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy.
Sledge GW; Einhorn L; Nagy C; House K
Cancer; 1992 Nov; 70(10):2524-8. PubMed ID: 1423181
[TBL] [Abstract][Full Text] [Related]
6. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
[TBL] [Abstract][Full Text] [Related]
7. Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results.
Hainsworth JD; Hesketh PJ
Semin Oncol; 1992 Dec; 19(6 Suppl 15):14-9. PubMed ID: 1485176
[TBL] [Abstract][Full Text] [Related]
8. A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
Ahn MJ; Lee JS; Lee KH; Suh C; Choi SS; Kim SH
Am J Clin Oncol; 1994 Apr; 17(2):150-6. PubMed ID: 8141107
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group.
Lebeau B; Depierre A; Giovannini M; Rivière A; Kaluzinski L; Votan B; Hédouin M; d'Allens H
Ann Oncol; 1997 Sep; 8(9):887-92. PubMed ID: 9358940
[TBL] [Abstract][Full Text] [Related]
10. Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.
Cheirsilpa A; Ratanatharathorn V; Sinlarat P; Chindavijak K; Lousoontornsiri W; Chakrapee-Sirisuk S; Srimuninimit V
J Med Assoc Thai; 1994 Apr; 77(4):201-6. PubMed ID: 7844494
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. S3AA3012 Study Group.
Needles B; Miranda E; Garcia Rodriguez FM; Diaz LB; Spector J; Craig J; Cohen G; Krasnow S; Brogden J; Ames M
Support Care Cancer; 1999 Sep; 7(5):347-53. PubMed ID: 10483821
[TBL] [Abstract][Full Text] [Related]
12. [Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo].
Ohta J; Taguchi T; Furue H; Niitani H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Suminaga M
Gan To Kagaku Ryoho; 1992 Oct; 19(12):2041-55. PubMed ID: 1417013
[TBL] [Abstract][Full Text] [Related]
13. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group.
Ruff P; Paska W; Goedhals L; Pouillart P; Rivière A; Vorobiof D; Bloch B; Jones A; Martin C; Brunet R
Oncology; 1994; 51(1):113-8. PubMed ID: 8265095
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials.
Beck TM
Semin Oncol; 1992 Dec; 19(6 Suppl 15):20-5. PubMed ID: 1485178
[TBL] [Abstract][Full Text] [Related]
15. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.
Navari RM; Madajewicz S; Anderson N; Tchekmedyian NS; Whaley W; Garewal H; Beck TM; Chang AY; Greenberg B; Caldwell KC
J Clin Oncol; 1995 Sep; 13(9):2408-16. PubMed ID: 7666101
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin > or = 100 mg/m2.
Kris MG; Clark RA; Tyson LB; Hahne WF; Pisters KM; Gralla RJ
Am J Clin Oncol; 1993 Feb; 16(1):77-80. PubMed ID: 8424410
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group.
Seynaeve C; Schuller J; Buser K; Porteder H; Van Belle S; Sevelda P; Christmann D; Schmidt M; Kitchener H; Paes D
Br J Cancer; 1992 Jul; 66(1):192-7. PubMed ID: 1386245
[TBL] [Abstract][Full Text] [Related]
18. Ondansetron suppository: an effective treatment for the prevention of emetic disorders induced by cisplatin-based chemotherapy. French Ondansetron Study Group.
Fumoleau P; Giovannini M; Rolland F; Votan B; Paillarse JM
Oral Oncol; 1997 Sep; 33(5):354-8. PubMed ID: 9415336
[TBL] [Abstract][Full Text] [Related]
19. [Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin].
Suminaga M; Furue H; Taguchi T; Ota K; Niitani H; Tsukagoshi S; Ariyoshi Y; Ikeda M; Ohta J; Akasaka Y
Gan To Kagaku Ryoho; 1992 Aug; 19(9):1333-45. PubMed ID: 1386975
[TBL] [Abstract][Full Text] [Related]
20. Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo.
Gandara DR; Harvey WH; Monaghan GG; Perez EA; Hesketh PJ
Eur J Cancer; 1993; 29A Suppl 1():S35-8. PubMed ID: 8427724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
